706 related articles for article (PubMed ID: 22133194)
1. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
Ravindran R; Maji M; Ali N
Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
[TBL] [Abstract][Full Text] [Related]
2. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
Mazumder S; Maji M; Ali N
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
[TBL] [Abstract][Full Text] [Related]
3. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
4. Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.
Ravindran R; Bhowmick S; Das A; Ali N
BMC Microbiol; 2010 Jun; 10():181. PubMed ID: 20576102
[TBL] [Abstract][Full Text] [Related]
5. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
Bhowmick S; Ravindran R; Ali N
BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
7. Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection.
Das A; Ali N
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3091. PubMed ID: 25144181
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble
Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727
[TBL] [Abstract][Full Text] [Related]
9. The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.
Emami T; Rezayat SM; Khamesipour A; Madani R; Habibi G; Hojatizade M; Jaafari MR
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):324-333. PubMed ID: 29607698
[TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccine from whole Leishmania donovani antigens provides protection and induces specific immune response against visceral leishmaniasis.
Helou DG; Mauras A; Fasquelle F; Lanza JS; Loiseau PM; Betbeder D; Cojean S
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009627. PubMed ID: 34403413
[TBL] [Abstract][Full Text] [Related]
11. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
[TBL] [Abstract][Full Text] [Related]
12. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
14. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice.
Mazumder S; Ravindran R; Banerjee A; Ali N
Vaccine; 2007 Dec; 25(52):8771-81. PubMed ID: 18031874
[TBL] [Abstract][Full Text] [Related]
15. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
16. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
[TBL] [Abstract][Full Text] [Related]
18. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
19. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
Das P; Paik D; Naskar K; Chakraborti T
Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
[TBL] [Abstract][Full Text] [Related]
20. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
